Business Wire

TMRW

7.12.2021 15:50:06 CET | Business Wire | Press release

Share
Sunny Varkey Launches Tmrw, a New Learning Operating System (LearnOS) for Global Education to Bring a Quality Education Within Reach of Every Child

Tmrw, a new and scalable Learning Operating System (LearnOS) for global education with a mission to help bring a quality education to every child, was launched this month.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005768/en/

Its interoperable All-In-One Integrated Platform is built to be accessible and affordable for Government funded schools operating in both the developed and developing world settings. In particular, it seeks to reach all students irrespective of their background or their ability to pay. It is designed to cater to the needs of every curriculum, context and mode of learning, whether brick and mortar, virtual or blended. Tmrw’s vision over time is to underpin learning, teaching, and the operational needs of K12 education, higher education and life-long learning.

Sunny Varkey, who also founded the Global Teacher Prize, has ensured that Tmrw has been teacher-led from the drawing board to its final roll-out. Uniquely, he has been able to draw upon the teaching talent within the GEMS schools network, which includes 20,000 inspired and qualified teachers, teaching support staff and school administrators from all nationalities, delivering seven different curricula in 16 countries.

The ongoing COVID-19 pandemic has emphasised the urgent need for an integrated technological solution for global education that can streamline end-to-end processes and utilise data to improve teaching and learning, while providing a seamless experience for all. Tmrw seeks to fill this void by providing an education eco-system that offers far more than a traditional, stand-alone learning or school management system. Working in collaboration with schools and teachers, our ambition is that Tmrw becomes an accepted LearnOS of global education – giving every learner an opportunity to participate in the future.

Tmrw’s EdTech platform includes a comprehensive suite of modules that can be introduced as a full ecosystem or as bolt-ons that are interoperable with technologies from other providers, offering schools the efficiency gains that integration can bring.

The platform includes modules to manage and oversee the curriculum, assessment, and track student progress. It has non-academic functionalities such as sports management, counselling and well-being. It allows schools to manage parent and student relations and includes custom-built health and child safety guarding features. It also includes back-office operations such as revenue management, HR, payroll, finance and procurement.

Tmrw is not just a technology company, but an education transformation company that offers comprehensive educational services such as:

  • Tmrw Academy – focused on professional development including teacher training
  • Education Command Center – serving policy makers with real-time decision-making capabilities at a national level
  • Tech-In-A-Box – Comprehensive technology backbone covering the school eco system end to end.
  • Tmrw Advisory Services for educational institutions on curriculum design, digital transformation, school improvement and nation-wide educational strategies.

Spun out from GEMS Education, Tmrw has been incorporated as the independent technology entity of GEMS and so will draw on the experience of the largest private K-12 education provider in the world, where its solutions have proven themselves to be scalable and effective with real students in a real classroom environment. GEMS Education, since it was founded 62 years ago, has provided a quality and values driven education throughout the world.

During the pandemic, GEMS Education moved seamlessly online from the start of the crisis because for the last decade it has built, tested, and constantly improved an education platform with real teachers and real students in real classrooms. This culture of improvement, driven both by analytics and constant engagement with the experience of teachers and partners, will be at the heart of Tmrw.

Today, GEMS is the only private-sector education operator with an all-inclusive platform for teachers, pupils, and parents. That experience is the foundation of Tmrw, which seeks to create an impact on a billion learners through technology, backed by a team that has touched millions of lives over decades.

Mr. Sunny Varkey, Chairman and Founder of Tmrw and GEMS Education, said:

“Quality education is the great equaliser. It bridges the gap between the rich and the poor and gives us the greatest opportunity to improve the state of our world.

“We have built this platform to be accessible and affordable for Government funded schools throughout the world to help improve learning outcomes wherever we can. We seek to reach all students irrespective of their background or their ability to pay. Ultimately, our vision is to give every child their birth-right of a great education and provide hope for a better future.

“We can only achieve this mission if we learn lessons from the frontline of education. For far too long edtech has side-lined the voice of the teacher. Not this time, as teachers will be the beating heart of Tmrw. They will be our designers, our content creators and our toughest critics.”

Tmrw CEO and GEMS Education Group Chief Disruption Officer, Mr Krishnan Gopi, said:

“Education is transforming at pace, moving away from the conventional patterns of teaching and learning that have dominated the sector. There is an undeniable, growing awareness among educators and families that education must evolve to meet tomorrow’s reality.

“Designed by educators for educators, Tmrw will help students learn better, teachers teach better, parents become more engaged, and schools become more efficient”.

Our platform is secure, scalable, multi-lingual and highly configurable to meet different needs of education systems across the globe. It utilizes exponential technologies such as AI / ML, AR /VR, Blockchain and IOT to revolutionise the teaching and learning experience.

*For more information about how Tmrw can empower schools to deliver enhanced teaching and learning outcomes please email: info@tmrw.group

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye